Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : biotech firesales -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (3164)	11/5/2014 2:35:58 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 3661

Phase III launched on back of data from a trial with four (4!) control patients that subset-parsed triple neg and antigen over-expression. Down 20% for a delay in "Hail Mary"? edit: Read release and twitter stuff. Slow enrollment, yes. Trial design also gets major face lift. Management has bozo egg on face.

To: tuck who wrote (3164)	11/5/2014 4:22:05 PM
From: biofisher	Read Replies (2) \| Respond to of 3661

This is clearly bad news on one of their more important programs. But it is just one from a fairly rich but longer term pipeline. I sold half my position long enough ago that I can't remember when. Big volume today but still closing well above a number of past year's daily lows. And some news upcoming on Rindo at SNO. So caution in order. As for my remaining stake, it will suffice for the foreseeable future. I'll just tuck it away. Milt